ArticleJournal of inflammation (London, England)2020
NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway.
Article in Journal of inflammation (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Impact of Adlay-Based Formula on Pain and Discomfort in Women with Dysmenorrhea: A Randomized Controlled Trial.Nutrients · 2024Trial
- Anti-Gingivitis and Anti-Osteoclastogenesis Effects of Ethanol Extract fromJournal of microbiology and biotechnology · 2026Article
- Electroacupuncture alleviates Parkinson's disease-related pain by inhibiting microglial NLRP3-ASC inflammasome in the amygdala.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Recent Advances (2020-2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies-A Comprehensive Review.Cancer management and research · 2026Review
- Ge-Gen Decoction Modulates the HSP90/AKT Signaling Pathway and the NLRP3 Inflammasome to Alleviate Primary Dysmenorrhea.Journal of pain research · 2026Article
- Baicalin MitigatesAnimals : an open access journal from MDPI · 2025Article
- Electroacupuncture and Parecoxib Reduce Inflammatory Injury in a Primary Dysmenorrhea Rat Model: Investigating the Role of the COX-2/NF-κB/NLRP3 Pathway.Journal of pain research · 2025Article
- Construction and application of a precise evaluation method for the quality of traditional Chinese medicine based on "target-combined quality evaluation" using safflower as an example.Frontiers in pharmacology · 2025Article
- Effects of low-frequency and high-frequency electroacupuncture pretreatment on the COX-2/mPGES-1/PGE2 pathway in a rat model of cold-coagulation dysmenorrhea.Frontiers in immunology · 2025Article
- Article
- Article
- Catalpol Alleviates Depression by Inhibiting NLRP3 Inflammasome via TLR4/MAPK/NF-Kb Pathway.Iranian journal of public health · 2023Article
- The relationship between spino-pelvic alignment and primary dysmenorrhea.Frontiers in surgery · 2023Article
- Ge-Gen Decoction Exerts an Anti-Primary Dysmenorrhea Effect in Rats by Inactivating the HSP90/NLRP3/NF-κB/COX-2 Pathway.Journal of inflammation research · 2023Article
- The Establishment of a Mouse Model of Recurrent Primary Dysmenorrhea.International journal of molecular sciences · 2022Article
- Acupuncture Alleviates Menstrual Pain in Rat Model via Suppressing Eotaxin/CCR3 Axis to Weak EOS-MC Activation.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Effects of wet cupping in a rat model of primary dysmenorrhea.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary dysmenorrhea (PD) constitutes a common gynecological disease among young women. The NLRP3 inflammasome may be activated and expressed in PD, but the mechanistic link between NLRP3 inflammasome activation and PD is still unclear.
methodsTo investigate the potential role of NLRP3 inflammasome activation in the pathogenesis of PD, 30 female Kunming mice without pregnancy were used for experiments. The PD mouse model was constructed by 11 days of successive co-treatment with estradiol and oxytocin. MCC950, a potent and specific small-molecule inhibitor of the NLRP3 inflammasome, was used to treat PD mice. The disease level was assessed by the writhing response and hot water tail-flick test. The levels of prostaglandin E
resultsMCC950 greatly ameliorated the writhing response induced by the combination of oxytocin and estradiol, with an increasing length of tail-flick latency. MCC950 also significantly decreased the levels of PGF
conclusionsMCC950 markedly alleviated the pain and pathological damage in PD mice by inhibiting NLRP3 activation. The underlying mechanism may be related to hypoactive uterine inflammation via suppression of NLRP3 activation and the NF-κB/COX-2/PG pathway in uteruses of PD mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.